ZBTB47

Summary

ZBTB47 (zinc finger and BTB domain containing 47, HGNC:26955) is a protein-coding gene on chromosome 3p22.1, encoding Zinc finger and BTB domain-containing protein 47 (Q9UFB7). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 92999 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 175 total — 1 pathogenic
• MANE Select transcript: NM_145166

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26955
Approved symbol	ZBTB47
Name	zinc finger and BTB domain containing 47
Location	3p22.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1190, DKFZp434N0615
Ensembl gene	ENSG00000114853
Ensembl biotype	protein_coding
OMIM	619969
Entrez	92999

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000232974, ENST00000505904, ENST00000680014, ENST00000889819, ENST00000889820, ENST00000889821, ENST00000889822, ENST00000889823

RefSeq mRNA: 2 — MANE Select: NM_145166 NM_001410746, NM_145166

CCDS: CCDS46805, CCDS93251

Canonical transcript exons

ENST00000232974 — 6 exons

Exon	Start	End
ENSE00000764558	42661485	42661632
ENSE00001498484	42658275	42659828
ENSE00001651725	42663012	42663127
ENSE00001671510	42653697	42653883
ENSE00001784559	42663797	42663941
ENSE00003848492	42664237	42667580

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 97.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.4357 / max 142.2280, expressed in 1656 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36274	11.7571	1650
36271	0.3411	207
36275	0.2594	127
36272	0.0780	30

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	97.29	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.58	gold quality
tibialis anterior	UBERON:0001385	96.13	gold quality
gastrocnemius	UBERON:0001388	95.96	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.51	gold quality
apex of heart	UBERON:0002098	95.43	gold quality
muscle of leg	UBERON:0001383	95.18	gold quality
myocardium	UBERON:0002349	94.69	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.44	gold quality
mucosa of stomach	UBERON:0001199	94.32	gold quality
heart left ventricle	UBERON:0002084	94.30	gold quality
pancreatic ductal cell	CL:0002079	94.22	silver quality
cardiac ventricle	UBERON:0002082	94.09	gold quality
amygdala	UBERON:0001876	94.08	gold quality
right coronary artery	UBERON:0001625	93.91	gold quality
putamen	UBERON:0001874	93.84	gold quality
parotid gland	UBERON:0001831	93.79	gold quality
cardiac atrium	UBERON:0002081	93.70	gold quality
spinal cord	UBERON:0002240	93.70	gold quality
right atrium auricular region	UBERON:0006631	93.65	gold quality
thoracic aorta	UBERON:0001515	93.12	gold quality
ascending aorta	UBERON:0001496	93.10	gold quality
aorta	UBERON:0000947	92.94	gold quality
heart	UBERON:0000948	92.92	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	92.92	gold quality
popliteal artery	UBERON:0002250	92.88	gold quality
tibial artery	UBERON:0007610	92.87	gold quality
lateral globus pallidus	UBERON:0002476	92.77	gold quality
skeletal muscle tissue	UBERON:0001134	92.53	gold quality
vastus lateralis	UBERON:0001379	92.21	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.28

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2543.1	ZBTB47	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605320

miRNA regulators (miRDB)

102 targeting ZBTB47, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466

Literature-anchored findings (GeneRIF, showing 2)

• Data show that ZNF651 is a ZNF652 paralogue that shares a common DNA binding sequence with ZNF652 and represses target gene expression through the formation of a CBFA2T3-ZNF651 corepressor complex. (PMID:20116376)
• De novo missense variants in ZBTB47 are associated with developmental delays, hypotonia, seizures, gait abnormalities, and variable movement abnormalities. (PMID:37743782)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	zbtb47a	ENSDARG00000057751
danio_rerio	zbtb47b	ENSDARG00000079547
mus_musculus	Zbtb47	ENSMUSG00000013419
rattus_norvegicus	Zbtb47	ENSRNOG00000019382
drosophila_melanogaster	dwg	FBGN0000520
drosophila_melanogaster	CG6654	FBGN0038301
caenorhabditis_elegans		WBGENE00003933

Paralogs (6): ZNF324 (ENSG00000083812), GTF3A (ENSG00000122034), ZUP1 (ENSG00000153975), ZNF513 (ENSG00000163795), ZNF652 (ENSG00000198740), ZNF324B (ENSG00000249471)

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 47 — Q9UFB7 (reviewed: Q9UFB7)

Alternative names: Zinc finger protein 651

All UniProt accessions (3): Q9UFB7, A0A7P0T820, D6RDG5

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UFB7-1	1	yes
Q9UFB7-2	2

RefSeq proteins (2): NP_001397675, NP_660149* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR049524	ZBTB47_BTB_POZ	Domain

Pfam: PF00096, PF00651

UniProt features (24 total): zinc finger region 9, compositionally biased region 4, sequence conflict 4, region of interest 2, chain 1, domain 1, cross-link 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UFB7-F1	54.34	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 190

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 60 (showing top): GCACCTT_MIR18A_MIR18B, TGGTGCT_MIR29A_MIR29B_MIR29C, chr3p22, TGACATY_UNKNOWN, HTF_01, HIF1_Q3, MYB_Q3, HOOI_ST7_TARGETS_DN, ACTTTAT_MIR1425P, RASHI_RESPONSE_TO_IONIZING_RADIATION_5, AP4_01, CCAWNWWNNNGGC_UNKNOWN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP, YTAAYNGCT_UNKNOWN, XBP1_01

GO Biological Process (1): regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (5): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

724 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB47	CBFA2T3	O75081	662
ZBTB47	C11orf71	Q6IPW1	533
ZBTB47	RWDD2A	Q9UIY3	476
ZBTB47	KIAA1755	Q5JYT7	436
ZBTB47	ZC3H6	P61129	421
ZBTB47	RNF103	O00237	403
ZBTB47	XKR5	Q6UX68	396
ZBTB47	SS18L2	Q9UHA2	379
ZBTB47	PIK3CA	P42336	371
ZBTB47	TIGD1	Q96MW7	365
ZBTB47	PRDM11	Q9NQV5	359
ZBTB47	NEDD9	Q14511	353
ZBTB47	RBM4B	Q9BQ04	348
ZBTB47	SEC22C	Q9BRL7	348
ZBTB47	USP54	Q70EL1	342

IntAct

47 interactions, top by confidence:

A	B	Type	Score
DENND10	CCDC93	psi-mi:“MI:0914”(association)	0.770
TLE5	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
ZNF394	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
ZBTB47	HOOK1	psi-mi:“MI:0915”(physical association)	0.560
ZBTB47	ZRANB1	psi-mi:“MI:0915”(physical association)	0.560
CEP70	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
ZBTB47	PNMA3	psi-mi:“MI:0915”(physical association)	0.560
DVL3	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
NCKIPSD	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
ZNF16	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
HOOK2	ZBTB47	psi-mi:“MI:0915”(physical association)	0.560
CBFA2T3	ZBTB47	psi-mi:“MI:0915”(physical association)	0.400
CUL4B	GGTLC3	psi-mi:“MI:0914”(association)	0.350
ZBTB47	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350
ZBTB47	TLE5	psi-mi:“MI:0915”(physical association)	0.000
ZBTB47	ZNF394	psi-mi:“MI:0915”(physical association)	0.000
ZBTB47		psi-mi:“MI:0915”(physical association)	0.000
ZBTB47	MTUS2	psi-mi:“MI:0915”(physical association)	0.000
ZBTB47	HOOK1	psi-mi:“MI:0915”(physical association)	0.000
ZBTB47	ZRANB1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (148): ZBTB47 (Two-hybrid), ZBTB47 (Affinity Capture-MS), ZBTB47 (Affinity Capture-MS), ZBTB47 (Affinity Capture-MS), ZBTB47 (Two-hybrid), ZBTB47 (Two-hybrid), ZBTB47 (Two-hybrid), ZBTB47 (Two-hybrid), CCDC136 (Two-hybrid), CBFA2T3 (Two-hybrid), MTUS2 (Two-hybrid), HOOK1 (Two-hybrid), ZNF394 (Two-hybrid), DVL3 (Two-hybrid), ZNF16 (Two-hybrid)

ESM2 similar proteins: A1L1J6, A2A5K6, A2APF3, D3ZUU2, E9Q8T2, G3V893, G5E8B9, O43167, O70237, O95625, P10074, P22227, P52739, P57071, P98169, Q05516, Q13105, Q1H9T6, Q3B725, Q3B7N9, Q3U288, Q3UH06, Q4VBD9, Q5DU09, Q5EAC5, Q5R633, Q5VTD9, Q60821, Q6DDV0, Q6GL52, Q6NS86, Q6YND2, Q6ZSB9, Q7TS63, Q80X44, Q8BKX7, Q8BXX2, Q8C8V1, Q8CCE9, Q8N1W2

Diamond homologs: A0A1B8YAB1, A1YPR0, B0WWP2, B1H285, B3M9V8, B3NDN0, B4GRJ2, B4HIK1, B4J045, B4L0G9, B4LIG6, B4MXW3, B4PD06, B4QLQ2, C9JR72, D3Z8N4, E0CZ16, G3X9X1, O15062, O88939, O93567, O95365, P28575, P41182, P41183, Q08CL3, Q08DK3, Q13105, Q16RL8, Q2M0J9, Q3UQV5, Q52KB5, Q5EXX3, Q5R7B8, Q5RDY3, Q5TC79, Q5ZI33, Q5ZKD9, Q5ZM39, Q60821

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ZBTB47	“form complex”	CBFA2T3/ZNF651	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

175 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	145
Likely benign	15
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1723211	NM_145166.4(ZBTB47):c.1429G>A (p.Glu477Lys)	Pathogenic

SpliceAI

1352 predictions. Top by Δscore:

Variant	Effect	Δscore
3:42658271:GCA:G	acceptor_loss	1.0000
3:42658272:CA:C	acceptor_loss	1.0000
3:42658273:A:AG	acceptor_gain	1.0000
3:42658273:AGTT:A	acceptor_gain	1.0000
3:42658274:G:GT	acceptor_gain	1.0000
3:42658274:GT:G	acceptor_gain	1.0000
3:42658274:GTT:G	acceptor_gain	1.0000
3:42658274:GTTG:G	acceptor_gain	1.0000
3:42658274:GTTGC:G	acceptor_gain	1.0000
3:42661483:A:AG	acceptor_gain	1.0000
3:42661483:AGTGT:A	acceptor_gain	1.0000
3:42661484:G:GG	acceptor_gain	1.0000
3:42661484:GT:G	acceptor_gain	1.0000
3:42661484:GTGT:G	acceptor_gain	1.0000
3:42661484:GTGTG:G	acceptor_gain	1.0000
3:42661614:GTGC:G	donor_gain	1.0000
3:42661629:GTTG:G	donor_gain	1.0000
3:42663939:CAGG:C	donor_loss	1.0000
3:42663940:AGGT:A	donor_loss	1.0000
3:42663942:GT:G	donor_loss	1.0000
3:42664228:A:AG	acceptor_gain	1.0000
3:42664229:A:G	acceptor_gain	1.0000
3:42664230:C:G	acceptor_gain	1.0000
3:42664235:A:AG	acceptor_gain	1.0000
3:42664235:AG:A	acceptor_gain	1.0000
3:42664236:G:GA	acceptor_gain	1.0000
3:42664236:GG:G	acceptor_gain	1.0000
3:42664236:GGA:G	acceptor_gain	1.0000
3:42664236:GGAGA:G	acceptor_gain	1.0000
3:42658264:T:A	acceptor_gain	0.9900

AlphaMissense

4922 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:42659667:T:C	C438R	1.000
3:42659676:T:A	C441S	1.000
3:42659676:T:C	C441R	1.000
3:42659677:G:C	C441S	1.000
3:42659688:T:C	F445L	1.000
3:42659689:T:C	F445S	1.000
3:42659690:C:A	F445L	1.000
3:42659690:C:G	F445L	1.000
3:42659748:T:C	C465R	1.000
3:42659769:T:C	F472L	1.000
3:42659770:T:C	F472S	1.000
3:42659771:C:A	F472L	1.000
3:42659771:C:G	F472L	1.000
3:42661485:T:C	C492R	1.000
3:42661575:T:C	C522R	1.000
3:42661576:G:A	C522Y	1.000
3:42661584:T:C	C525R	1.000
3:42661585:G:A	C525Y	1.000
3:42661586:T:G	C525W	1.000
3:42661596:T:C	F529L	1.000
3:42661598:C:A	F529L	1.000
3:42661598:C:G	F529L	1.000
3:42661625:C:A	H538Q	1.000
3:42661625:C:G	H538Q	1.000
3:42663016:C:A	H542Q	1.000
3:42663016:C:G	H542Q	1.000
3:42663032:T:C	F548L	1.000
3:42663034:C:A	F548L	1.000
3:42663034:C:G	F548L	1.000
3:42663038:T:C	C550R	1.000

dbSNP variants (sampled 300 via entrez): RS1000150159 (3:42660475 G>GC), RS1000401886 (3:42655825 T>C), RS1000472013 (3:42663391 A>G), RS1000690527 (3:42653729 G>T), RS1000822056 (3:42660199 G>A,C), RS1000822976 (3:42663974 CG>C), RS1001145449 (3:42653949 G>A), RS1001308368 (3:42659919 G>C), RS1001488410 (3:42665685 G>A,C,T), RS1001554598 (3:42666688 G>A,T), RS1001792023 (3:42665492 T>C), RS1001893601 (3:42654266 A>C,G), RS1002257190 (3:42659025 G>A), RS1002412908 (3:42652533 G>A,C), RS1002492854 (3:42652951 C>A)

Disease associations

OMIM: gene MIM:619969 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (2): complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	affects expression, decreases expression	2
Tretinoin	decreases expression, increases expression	2
Valproic Acid	decreases expression, increases methylation	2
p-Chloromercuribenzoic Acid	affects cotreatment, affects expression	2
aristolochic acid I	decreases expression	1
dicrotophos	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, affects expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, affects expression	1
(+)-JQ1 compound	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	increases expression	1
Methyl Methanesulfonate	decreases expression	1
Smoke	decreases expression	1
Urethane	decreases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism